Navigation Links
LORENZ' Response to New EU PV Legislation - Regulation No. 1235/2010 and EVMPD
Date:11/2/2011

FRANKFURT AM MAIN, Germany, Nov. 2, 2011 /PRNewswire/ -- LORENZ customers and business partners have successfully completed the first workshop on the new Requirements of Article 57(2) of Regulation (EC) 726/2004 and its impact on the industry. This marked the start of the LORENZ Special Interest Group for EVMPD – XEVPRM.

One of the hot topics in the regulated market space of drug registration are the Requirements of Article 57(2) of Regulation (EC) 726/2004. Since the EU has mandated the European Medicines Agency (EMA) to build a database for all registered product information within the European Union, many organizations are discussing and planning how to cope with the challenge to supply relevant data within a very aggressive time schedule. The legislation is effective and mandatory as of 2nd July 2012. A quote from the EMA website reads: "The legislation is the biggest change to the regulation of human medicines in the European Union (EU) since 1995. It has significant implications for applicants and holders of European Union marketing authorizations."

With this in mind, a strategic group of LORENZ customers and business collaborators came together on 24th October 2011 at LORENZ Headquarters in Frankfurt, Germany. In this workshop the complexity of the undertaking became clear, and the challenging timelines were reviewed.

"The data model, ease of use and proven track record of supplying a data entry platform will be key for our customers and coworkers", says Wolfgang Witzel, President of LORENZ Life Sciences Group. "There are several facts that we have to accept. Firstly, the draft specification has only been available since 1st September 2011. Secondly, further guidance is outstanding and questions on the specification still needs to be answered. Thirdly, example messages are outstanding. Fourthly, vocabularies are outstanding. And finally, on the technology side, both the Gateway and EVWeb supplied by EMA are not ready. This is a huge challenge for industry."

"As a result, LORENZ believes this has to be planned carefully and adapted as the specification and guidance becomes more mature. It also means that any organisation offering a final solution today cannot be providing a serious offer and the buyer will possibly be paying a premium," Wolfgang Witzel continues.

Raoul-A. Lorenz, CEO of LORENZ Life Sciences Group, added, "LORENZ has the track record of being the most innovative provider of quality software and related services for e-regulated processes in the Life Sciences industry. As a result, LORENZ too will look into options in providing a validated product for this important process as well.  The ultimate goal is to comply to the future ISO IMPD standard, recognizing that the XEVPRM is an interim standard."

Further information about the meeting, progress of work and timelines will be distributed and can be accessed via LORENZ ID as of December 2011.

About LORENZ Life Sciences Group LORENZ Life Sciences Group (www.lorenz.cc) has been developing and marketing software solutions for the Life Sciences market since 1989. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management. As the number one supplier of submission management systems in the world, as well as the largest supplier of eCTDs for U.S., European and Japanese submissions in the world, LORENZ is the technological market leader. With over 200 installations in 25 countries, LORENZ has built a reputable customer base. For more information, please click here to contact LORENZ.


'/>"/>
SOURCE LORENZ Life Sciences Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
6. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
7. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
8. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
9. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
10. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... More than half of Americans suffering from noise-induced ... their leisure time that causes hearing loss? May 1 marks the beginning of Better ... hearing loss, as well as schedule a hearing evaluation for anyone with concerns about ...
(Date:4/28/2017)... Cary, NC (PRWEB) , ... April 28, 2017 ... ... to announce its new partnership with the Home Care Association of America (HCAOA). ... Hospice, and Private Duty Accreditation services, as well as discounts on Accreditation University ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... ... 28, 2017 , ... Ushio America proudly introduces the new ... energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts ... rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s ...
(Date:4/28/2017)... Texas (PRWEB) , ... April 28, 2017 , ... The ... plaque in recently to the labor and delivery team at Women’s Hospital at Renaissance ... mothers who give birth at the hospital and decide to donate. , “Women’s ...
Breaking Medicine News(10 mins):